[Menstrual abnormality in patients with breast cancer receiving adjuvant endocrine-chemotherapy]
- PMID: 3140733
[Menstrual abnormality in patients with breast cancer receiving adjuvant endocrine-chemotherapy]
Abstract
Menstrual status and ovarian function were studied in 24 premenopausal breast cancer patients receiving adjuvant therapy with chemotherapy and tamoxifen or chemotherapy alone. In 13 of 24 patients (54.1%), abnormal menses, including amenorrhea in 12 cases and oligomenorrhea in 1 case, developed during adjuvant therapy. In patients with abnormal menses, serum estradiol was significantly lower, and the levels of gonadotropins were significantly higher than in patients with normal menses. Among 13 patients with abnormal menses, 4 patients treated with cyclophosphamide revealed persistent amenorrhea during the whole period with adjuvant therapy, and the levels of serum estradiol and progesterone were extremely low. Furthermore, in these patients normal menses has not recovered and the levels of serum estradiol and progesterone remained low 4 to 5 months after cessation of cyclophosphamide administration. Thus, adjuvant chemotherapy caused depression of ovarian function, and cyclophosphamide induced ovarian failure, resulting in complete amenorrhea.
Similar articles
-
Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen.Cancer Res. 1988 Feb 15;48(4):1026-9. Cancer Res. 1988. PMID: 3123050
-
[Observation and clinical significance of adjuvant chemotherapy-induced amenorrhea in premenopausal breast cancer patients].Zhonghua Zhong Liu Za Zhi. 2006 Nov;28(11):848-51. Zhonghua Zhong Liu Za Zhi. 2006. PMID: 17416008 Chinese.
-
Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: comparison between tamoxifen-treated and nontreated breast cancer patients.Gynecol Oncol. 1999 Feb;72(2):202-7. doi: 10.1006/gyno.1998.5201. Gynecol Oncol. 1999. PMID: 10021302 Clinical Trial.
-
Ovarian function and childbearing issues in breast cancer survivors.Gynecol Endocrinol. 2007 Nov;23(11):625-31. doi: 10.1080/09513590701582406. Gynecol Endocrinol. 2007. PMID: 17926162 Review.
-
Which factors should be taken into account in perimenopausal women with early breast cancer who may become eligible for an aromatase inhibitor? Recommendations of an expert panel.Cancer Treat Rev. 2011 Apr;37(2):97-104. doi: 10.1016/j.ctrv.2010.05.005. Epub 2010 Jul 1. Cancer Treat Rev. 2011. PMID: 20594763 Review.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical